The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | The promise of allogeneic CAR-T cell products for the treatment of hematological malignancies
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the growing role of allogeneic CAR-T cell products for the treatment of hematological malignancies, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Dr Jain first explains the challenges of using autologous CAR-T products in clinical practice, and then goes on to discuss the advantages of allogeneic products, and where these may fit in the treatment landscape of these hematological malignancies. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
